Commonwealth Equity Services LLC Trims Stock Holdings in Haleon plc (NYSE:HLN)

Commonwealth Equity Services LLC decreased its position in Haleon plc (NYSE:HLN) by 1.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 256,730 shares of the company’s stock after selling 4,655 shares during the period. Commonwealth Equity Services LLC’s holdings in Haleon were worth $2,180,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hexagon Capital Partners LLC grew its position in shares of Haleon by 107.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 4,236 shares of the company’s stock valued at $35,000 after acquiring an additional 2,193 shares during the period. Pinnacle Bancorp Inc. boosted its holdings in Haleon by 853.4% in the 4th quarter. Pinnacle Bancorp Inc. now owns 4,767 shares of the company’s stock worth $39,000 after buying an additional 4,267 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Haleon in the 1st quarter worth about $43,000. Tower Research Capital LLC TRC boosted its holdings in Haleon by 146.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,398 shares of the company’s stock worth $44,000 after buying an additional 3,211 shares during the last quarter. Finally, SRS Capital Advisors Inc. boosted its holdings in Haleon by 456.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 5,458 shares of the company’s stock worth $45,000 after buying an additional 4,477 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HLN shares. Berenberg Bank started coverage on Haleon in a report on Wednesday, June 5th. They issued a “buy” rating on the stock. Argus reissued a “buy” rating on shares of Haleon in a research note on Tuesday, March 26th. Finally, HSBC started coverage on shares of Haleon in a research note on Wednesday, April 17th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Haleon has an average rating of “Moderate Buy”.

Haleon Trading Down 0.1 %

Haleon stock traded down $0.01 during trading on Friday, hitting $8.45. The company had a trading volume of 1,511,640 shares, compared to its average volume of 5,308,539. Haleon plc has a 1-year low of $7.70 and a 1-year high of $8.96. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.53. The company’s 50 day simple moving average is $8.41 and its 200-day simple moving average is $8.35. The stock has a market cap of $38.58 billion, a price-to-earnings ratio of 28.17, a price-to-earnings-growth ratio of 2.25 and a beta of 0.24.

Haleon (NYSE:HLN) last posted its earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. Haleon had a net margin of 9.68% and a return on equity of 13.17%. The firm had revenue of $3.70 billion during the quarter, compared to the consensus estimate of $3.71 billion. As a group, analysts expect that Haleon plc will post 0.46 EPS for the current fiscal year.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.